Staurosporine

Catalog No.S1421 Synonyms: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Size Price Stock Quantity  
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Targets
PKCα [1]
(Cell-free assay)
c-Fgr [2] phosphorylase kinase [2] PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells M1\vNGN6fG:2b4jpZ:Kh[XO|YYm= NHS0e4c1QCCq M{X3NmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20[U0xPiEQvF2u MV[yNVM5QDF7MR?=
human colon cancer cell line (LoVo cells) M1T0NXBzd2yrZnXyZZRqd25iYYPzZZk> MoW1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiClb3zvckBk[W6lZYKgZ4VtdCCuaX7lJEhNd1[xIHPlcIx{MSC3c3nu[{BOXFRiYYPzZZktKEmFNUC9NE4xODFizszNMi=> NIfPNJMyOTV7MUWwOS=>
human LoVo cells MXnQdo9tcW[ncnH0bY9vKGG|c3H5 M4q4WFQ5KHSxIEeyJIg> NEDDOWNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzvWo8h[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigQ>? M1PvTlIzOTh{OUK5
P19 cells NXrNe|UxTnWwY4Tpc44h[XO|YYm= MVHJcohq[mm2aX;uJI9nKFCuYYTlcIV1NWSncnn2[YQh\3Kxd4ToJIZi[3SxcjDy[YNmeHSxcjDpckBROTliY3XscJMtKEmFNUC9NE4xODJizszNMi=> MUmxOVc4OTRzOR?=
human BJ cells M{Lve2N6fG:2b4jpZ:Kh[XO|YYm= Ml3wO|IhcA>? Ml;2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPhcINmcW5iQV2gZZN{[XluIFnDOVA:OC5yMEKg{txONg>? MWqyNlkzOTB6MR?=
human HT-29 cells NWH4OHFOTnWwY4Tpc44h[XO|YYm= NEfHd4kzKGh? MlXKSYZn\WO2IH;uJI1qfG:laH;u[JJq[WxibXXtZpJidmVicH;0[Y51cWGuIHnuJIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEKgbJJ{KHW|aX7nJGpENTFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGG|c3H5 MlL3NlE1Ojh|N{W=
human A549 cells Ml\kR5l1d3SxeHnjxsBie3OjeR?= M3\BTFczKGh? NXfh[lFtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBu\XSqb3S= MX2xPFQ5PDd5NR?=
human HT-29 cells MlqySpVv[3Srb36gZZN{[Xl? MoPFTY5pcWKrdHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBqdiCqdX3hckBJXC1{OTDj[YxteyC3c3nu[{BLSzFiZInlJJN1[WmwaX7nJIJ6KG[udX;y[ZNk\W6lZTDwcIF1\SC{ZXHk[ZIh[XO|YYmsJGlEPTB;Mj61JI5O MVWyNVUyOzJ7Mx?=
human HT-29 cells M1Hkd2Z2dmO2aX;uJIF{e2G7 M4Ljd|IhcA>? MXvJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiWLUK5JINmdGy|IHHzd4V{e2WmIILl[JVkfGmxbjDv[kBucXSxY3jvcoRzcWGuIH3lcYJz[W6nIIDveIVvfGmjbDDh[pRmeiB{IHjyd{BjgSC3c3nu[{BLSzFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGOnbHytZoF{\WRiYYPzZZktKEWFNUC9Nk43KG6PLh?= MnXMNlE6PzNzMEG=
Sf9 cells NYrjVG5QTnWwY4Tpc44h[XO|YYm= M4OxN2lvcGmkaYTpc44hd2ZiaIXtZY4hW3mtIHX4dJJme3OnZDDpckBU\jliY3XscJMtKEmFNUC9N{BvVS5? MYqxPFgzOzd6NB?=
human HUVEC NF;OW3ZRem:uaX\ldoF1cW:wIHHzd4F6 M4XhVlQ5KHSxIEeyJIg> NH;4cllCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVEKGGodHXyJFQ5KHSxIEeyJIhzeyCkeTDNWHQh[XO|YYm= M{PH[VIzOTh{OUK5
P19 cells MmDCSpVv[3Srb36gZZN{[Xl? M1:zWmlvcGmkaYTpc44hd2ZiUILveIVqdiCNaX7hd4UhSSCrbjDQNVkh[2WubIOsJGlEPTB;NDDuUU4> MYWxOVc4OTRzOR?=
Sf9 cells M2ro[WZ2dmO2aX;uJIF{e2G7 NWTzepE{UW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAyKG2rbjDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGC= NHK3N|cyPzNzNUi1Ny=>
Sf21 cells NFjaSWlHfW6ldHnvckBie3OjeR?= Ml7LTY5pcWKrdHnvckBw\iCMQVuzJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy|LDDJR|UxRTZibl2u MnnqNVcxQDhyNUm=
human colon carcinoma cell line HCT116 NHnzdWpHfW6ldHnvckBie3OjeR?= MXvDc45k\W62cnH0bY9vKHKncYXpdoVlKG[xcjDndo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDjc4xwdiClYYLjbY5wdWFiY3XscEBtcW6nIFjDWFEyPixiSVO1NF03KG6PLh?= M{O1bVE2PTN5M{S1
human ST486 cells NW\GSY5qWHKxbHnm[ZJifGmxbjDhd5NigQ>? NH3jdVY1QCC2bzC3NkBp M3KxU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2S0PFYh[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF04KG6PLh?= MkfDNlIyQDJ7Mkm=
human MDA-MB-231 cells Ml;ER5l1d3SxeHnjxsBie3OjeR?= MoXkO|IhcA>? NVX0cnBHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDt[ZRpd2RuIFfJOVA:Py5zIH7NMi=> M1\6V|E5PDh2N{e1
P19 cells MoXQSpVv[3Srb36gZZN{[Xl? NHTSeIdKdmirYnn0bY9vKG:oIFP5Z4xqdi2mZYDlcoRmdnRia3nuZZNmKDFiaX6gVFE6KGOnbHzzMEBKSzVyPUigcm0v NF\vUFIyPTd5MUSxPS=>
human DLD1 cells M4rpNXBzd2yrZnXyZZRqd25iYYPzZZk> NH3vXo81QC15MjDo Mkj3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGTFSxJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PUBvVS5? NVTEZoIyOjJzOEK5Nlk>
insect cells NVrWXWMyTnWwY4Tpc44h[XO|YYm= M{SzbGlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUHntNUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJIJ6KEiWUl[sJGlEPTB;MUCgcm0v NWLWS3pWOTlzN{mwO|Y>
V79 MZ cells MYnGeY5kfGmxbjDhd5NigQ>? MmrWTY5pcWKrdHnvckBw\iCqdX3hckBidGSxc4Tldo9v\SC|eX70bIF{\SCneIDy[ZN{\WRiaX6gWlc6KE2cIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[Wymb4P0[ZJwdmVic4nueIhme2m|LDDJR|UxRTFzIH7NMi=> MUeyOFQzOjVzOR?=
P19 cells NUPFNpNsTnWwY4Tpc44h[XO|YYm= MXPJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTF2IH7NMi=> Ml7rNVU4PzF2MUm=
Sf9 cells MWTGeY5kfGmxbjDhd5NigQ>? MmHhNlAhdWmwcx?= M4rGWmlvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNlAhdWmwczDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGCsJGlEPTB;MUWgcm0v NULadFgzOTd|MUW4OVM>
human PBMC NFnTZXhHfW6ldHnvckBie3OjeR?= NX7ReHZoOjRiaB?= NYi1PYloW3WycILld5Nqd25ib3[gTWwzKHC{b3T1Z5Rqd25iaX6gbJVu[W5iUFLNR{Bi\nSncjCyOEBpenNiYomgSWxKW0FuIFnDOVA:OTZibl2u NH\0RXoyQDV6NUC0Oi=>
human A549 cells Mn:1R5l1d3SxeHnjxsBie3OjeR?= NULlcWc5PDhiaB?= NUizTY9nS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6KCxiSVO1NF0zOCCwTT6= MlS4NlU5OjV7M{S=
human CEM cells M372XmN6fG:2b4jpZ:Kh[XO|YYm= M1LkfVczKGh? M13yUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4Ft[2WrbjDBUUBie3OjeTygTWM2OD1{MzDuUU4> MYCyNlkzOTB6MR?=
human HeLa cells M1HL[WN6fG:2b4jpZ:Kh[XO|YYm= MVK0PEBp NXPqeZp[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI2KG6PLh?= MUWyOVgzPTl|NB?=
human PC3 cells NFTkeI5EgXSxdH;4bYPDqGG|c3H5 Mn\2OFghcA>? NHLOXFdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9N|Ehdk1w M1XDRlI2QDJ3OUO0
human SF268 cells NVuxbXZDS3m2b4TvfIlkyqCjc4PhfS=> M{HHRlQ5KGh? MnrUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzPjhiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME20OEBvVS5? MnPrNlE2OTN{OUS=
human MCF7 cells MlPRR5l1d3SxeHnjxsBie3OjeR?= NFPyXHE1QCCq M162Z2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21NEBvVS5? MnO2NlE{QDhzOUG=
HEK293 cells NWnDeYwyS3m2b4TvfIlkyqCjc4PhfS=> MoXjO|IhcA>? M1;sXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{R3zvJIF{e2G7LDDJR|UxRTV4IH7NMi=> MnvnNlQ4PjN{NkK=
HUE cells M3uxcWZ2dmO2aX;uJIF{e2G7 Ml\uPVAhdWmwcx?= Mln6TY5pcWKrdHnvckBw\iCYRVfGVlIhcW5iSGXFJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiVlXHSk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hfHKnYYTl[EBnd3JiOUCgcYlveyCkZX\vdoUhXkWJRjDjbIFtdGWwZ3WgZpkhTUyLU1GsJGlEPTB;N{Cgcm0v MUSyNFE4ODF4Mx?=
human A431 cells M1P0WmN6fG:2b4jpZ:Kh[XO|YYm= NEG5[YwzPCBiaB?= NH7WT3lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KGGodHXyJFI1KGi{czD1d4lv\yCDbn7lfIlvKF[nRlnUR{9xem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJ6KE2WVDDhd5NigSxiSVO1NF04OCCwTT6= NFjvXlQzOjV2MUC1NS=>
human Jurkat cells MVHQdo9tcW[ncnH0bY9vKGG|c3H5 NWLLU5NQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBLSUt|IHX4dJJme3OrbnegTWwzNXO2aX31cIF1\WRiaIXtZY4hUnW{a3H0JINmdGy|LDDJR|UxRTdzIH7NMi=> NV;UXJF7OTl2MkeyNFM>
HEK293 cells NWjPSWl1TnWwY4Tpc44h[XO|YYm= MkTDTY5pcWKrdHnvckBw\iCLTD24JJJmdGWjc3WgZpkhUEWNMkmzJINmdGy|IHX4dJJme3OrbnegVGtENWKndHGyMEBKSzVyPUe3JI5ONg>? NUHwR4FLOTV5N{G0NVk>
human KE-97 cells M2HTSmN6fG:2b4jpZ:Kh[XO|YYm= M3[3TlczKGh? MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLSU06PyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE{KM7:TT6= MYSyOFMzQDJ6Mx?=
human CHOK1 cells MX3DfZRwfG:6aXRCpIF{e2G7 Mni3OFghcA>? MmjOR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2hQUzFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOTNizszNMi=> NFyx[nEzOTVzM{K5OC=>
mouse NIH/3T3 cells MYrDfZRwfG:6aXRCpIF{e2G7 NID0UGI6PiCq MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDOTWgwO1R|IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= MnHwNlQ{PjF3MkG=
human A2780 cells MULDfZRwfG:6aXRCpIF{e2G7 M3\XV|k3KGh? MlzoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= MXGyOFM3OTV{MR?=
human 8505C cells NHnPSXREgXSxdH;4bYPDqGG|c3H5 NXvOWnNlQTZiaB?= MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjC4OVA2SyClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNkDPxE1w MVyyOFM3OTV{MR?=
human 518A2 cells Ml75R5l1d3SxeHnjxsBie3OjeR?= MVm5OkBp M3TVO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFUyQEF{IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjJizszNMi=> MlnlNlQ{PjF3MkG=
human HuH7 cells NILTSZVEgXSxdH;4bYPDqGG|c3H5 MVS3NkBp NGHRT21EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJfUh5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjNizszNMi=> NYDKZnVmOjR|MkiyPFM>
FL5.12-Akt1 cells NV;EPJZ4WHKxbHnm[ZJifGmxbjDhd5NigQ>? MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\MOU4yOi2Da4SxJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlI6KM7:TT6= M2T2WlE3PDB|NkK2
human MiaPaCa-2 cells Ml\6VJJwdGmoZYLheIlwdiCjc4PhfS=> M3XW[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTXnhVIFE[S1{IHPlcIx{NCCLQ{WwQVAvOzdizszNMi=> M{Xie|E3PDF|N{iw
human BGC823 cells MorWR5l1d3SxeHnjxsBie3OjeR?= M4C3NlczKGh? NXq4NodTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkeFOEKzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1emVvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{ig{txONg>? MkTzNlQ{Ojh{OEO=
human MCF7 cells MWjDfZRwfG:6aXRCpIF{e2G7 MoTLPVYhcA>? MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD60JO69VS5? NXLXfW1yOjR|NkG1NlE>
human A549 cells MWfDfZRwfG:6aXRCpIF{e2G7 M{DtPFk3KGh? NYXXR3c{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPiEQvF2u NG\rRZQzPDN4MUWyNS=>
HEK293 cells M33TZWN6fG:2b4jpZ:Kh[XO|YYm= M3\NWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczygSWM2OD1{IN88UU4> Ml\JNlU{OTZ|MUe=
human Raji cells  M{G4V2N6fG:2b4jpZ:Kh[XO|YYm= NGD0SVhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT[WqrIHPlcIx{NCCHQ{WwQVIh|ryPLh?= NFm4d|czPTNzNkOxOy=>
human HepG2 cells NUDTZ|NDS3m2b4TvfIlkyqCjc4PhfS=> Mm\qR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMtKEWFNUC9NkDPxE1w MXWyOVMyPjNzNx?=
human BJ cells MVTDfZRwfG:6aXRCpIF{e2G7 MkDjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOsJGVEPTB;MjFOwG0v Mm[5NlU{OTZ|MUe=
human U937 cells MlvpR5l1d3SxeHnjxsBie3OjeR?= M4Lt[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMtKEmFNUC9NkDPxE1w MU[xO|A5QDB4Nx?=

... Click to View More Cell Line Experimental Data

In vivo In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
Cell Research:

[3]

+ Expand
  • Cell lines: PC12
  • Concentrations: Dissolved in DMSO, final concentration 1 μM
  • Incubation Time: ~32 hours
  • Method:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (Only for Reference)
Animal Research:

[8]

+ Expand
  • Animal Models: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~10 ng
  • Administration: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.57 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 466.53
Formula

C28H26N4O3

CAS No. 62996-74-1
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Staurosporine | Staurosporine supplier | purchase Staurosporine | Staurosporine cost | Staurosporine manufacturer | order Staurosporine | Staurosporine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID